CRISPR-Cas12a/Cas13a in cancer molecular diagnosis

Comprehensive Summary

This review discusses how CRISPR-based technologies—particularly Cas12a and Cas13a—are being developed as new tools for cancer diagnosis. Traditional tissue biopsies can be invasive and often fail to capture the full genetic diversity of tumors, which has led researchers to explore liquid biopsies that detect tumor-related biomarkers in blood or other bodily fluids. While existing liquid biopsy techniques like next-generation sequencing and digital PCR are powerful, they can be expensive, technically complex, and sometimes lack sensitivity when biomarkers are present at very low levels. The article explains how CRISPR systems offer a promising alternative because they can be programmed to recognize specific DNA or RNA sequences and produce amplified detection signals. Cas12a is mainly used to detect DNA changes such as gene mutations and methylation patterns, while Cas13a can directly identify RNA molecules like microRNAs or viral RNA linked to cancer. Researchers have also adapted these systems to detect non-nucleic acid biomarkers—such as proteins and exosomes—by converting them into detectable signals. The review outlines recent progress in developing CRISPR-based biosensors while also acknowledging technical limitations that still need to be addressed before widespread clinical use.

Outcomes and Implications

For clinicians and researchers, this work highlights the potential for CRISPR-based diagnostics to transform early cancer detection and patient monitoring. If these technologies become clinically validated, they could enable faster, cheaper, and more sensitive testing through minimally invasive liquid biopsies. This would allow physicians to detect cancers earlier, track tumor evolution over time, and monitor treatment response without repeatedly relying on surgical tissue sampling. The possibility of point-of-care testing could also expand access to advanced molecular diagnostics in settings where complex laboratory infrastructure is not available. However, the article stresses that challenges—such as improving specificity, enabling simultaneous detection of multiple biomarkers, and establishing standardized clinical protocols—must be resolved before these tools can be integrated into routine medical practice.